PharmaResearch announced on the 3rd that it has signed a strategic investment agreement with the biotech venture company Connext and agreed to build a mid- to long-term partnership.

Connext develops biopharmaceuticals based on research and development and process technologies using protein recombination.

PharmaResearch previously signed a license-in agreement for Connext’s drug candidate “CNT201.” CNT201 is a biopharmaceutical that can be expanded to various indications ranging from aesthetic areas such as cellulite, Dupuytren’s contracture, and Peyronie’s disease to therapeutic areas. It recently completed Phase 1 clinical trials with the U.S. FDA and is currently in Phase 2.

Through this investment, PharmaResearch plans to secure priority rights to commercialize CNT201 and to pursue active business partnerships based on Connext’s technology.

A PharmaResearch official stated, “With this investment as a starting point, the two companies will work together more closely to accelerate the commercial success of CNT201 and the development of next-generation pipelines.”

Popular News